NCT02829034 - Targeting Right Ventricle in Pulmonary Hypertension Gilead | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2018

Conditions

Pulmonary Hypertension

Interventions

DRUG

Ranolazine

Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.

DRUG

Placebo

Placebo by mouth twice per day for a total of 26 weeks

Trial Locations (3)

University of Pennsylvania, Philadelphia

University of Maryland, Baltimore

Brigham and Women's Hospital, Boston